Organic Active Ingredients TRIZ Cases

Microalgae extracellular vesicles bypass environmental barriers to deliver cargo to the brain, solving mammalian EV limitations.

A Spinacea oleracea formulation promotes bone anabolic effects through oral administration of specific flavone compounds.

Replacing hydrogenation with organolithium nucleophilic addition resolves stereoisomer selectivity and yield trade-offs in indole ester synthesis.

Reversible imidazopyridine derivatives block gastric acid secretion via H+/K+-ATPase binding, avoiding irreversible PPI adverse effects.

Alkyl-amide-substituted pyridyl compounds inhibit Tyk2 to reduce IL-12 and IL-23 driven inflammation.

Roller compaction increases L-tryptophan bulk density, reducing excipient volume and dosage form size in pharmaceutical compositions.

2,5,6-substituted morpholine derivatives inhibit HIV protease while reducing adverse effects and metabolic clearance.

Replacing peanut oil and soy lecithin with type II safflower oil eliminates allergenic reactions while maintaining physiological progesterone levels.

A transfection composition directs genetic material away from acidic compartments and stabilizes microtubules to enhance intracellular trafficking.

Pre-treatment skin testing identifies patients at risk of anaphylaxis, angioedema, and skin rashes before initiating iloperidone therapy.

Azobenzene-modified siRNAs undergo cis-trans isomerization under UV or visible light, enabling precise spatial and temporal control of RNA silencing activity.

A polyplex conjugate targets PSMA to deliver double-stranded RNA alongside immune checkpoint modulators.

A phosphate buffer system prevents adsorption of dexmedetomidine by plastic materials, reducing drug loss while maintaining therapeutic efficacy.

Formula II and III compounds inhibit Aurora kinase to arrest cell cycling, resolving limited treatment effectiveness.

Benzimidazole derivatives release Ligustrazine and NO to synergize with Azilsartan, reducing adverse effects while protecting liver and kidney functions.

Acid addition salts of 2,6-dimethylpyrimidone derivatives resolve polymorphism issues to improve stability and bioavailability.

mGluR8 inhibitors resolve treatment effectiveness gaps by selectively targeting mGluR8-associated cancers while minimizing off-target effects.

Cationic steroidal antimicrobial compounds accelerate healing by stimulating fibroblastic migration and epithelial growth, addressing slow tissue repair rates.

Substituted biphenyl carboxylic acids modulate gamma-secretase activity to alter amyloid-beta processing.

Defined substituents on the pyrazolo[4,3-c]isoquinoline core improve anti-cancer efficacy and specificity, resolving limitations in existing therapeutic agents.

Tranexamic acid in a wound dressing reduces exudate production, eliminating painful repeated dressing changes.

Soluble epoxide hydrolase inhibitors boost epoxyeicosatrienoic acids to clear amyloid-beta across the blood-brain barrier.

ZNF865 fusion proteins drive CRISPR-Cas systems to upregulate aggrecan and collagen II, addressing modest activation levels in degenerative disc disease.

SPHK2 inhibitors target the S1P axis to reduce pulmonary artery vascular remodeling and treat underlying pathophysiological mechanisms.

Rycals restore calcium channel function by strengthening Calstabin interactions, preventing sarcoplasmic reticulum leaks.

CGRP inhibition combined with PD-1 blockade overcomes tumor evasion mechanisms to reduce breast cancer volume and metastasis.

HSP90 inhibitory peptide conjugates link cytotoxic agents to tumor cells, reducing systemic adverse effects while enhancing antitumor efficacy.

A novel synthetic route for Sugammadex substitutes primary hydroxyl groups of gamma-cyclodextrin with halogens.

A peripherally restricted dual opioid agonist activates kappa and delta receptors to produce synergistic analgesia.

Antibodies bind TIKI proteins to block Wnt cleavage, increasing signaling for bone density treatment.

Merges immunotherapy with chemotherapy to expand cytotoxic CD8+ T-cells and reduce tumor burden.

Substituted furanyl compounds disrupt cap-dependent protein translation initiation to inhibit tumor growth while reducing toxicity to normal cells.

Acetaminophen interferes with viral replication pathways to protect host cells from cytotoxicity.

Carboxylated polyamine derivatives balance hydrophobic membrane penetration and solution stability to deliver RNA efficiently.

Formula IA compounds inhibit MAT2A enzyme activity to block S-adenosyl methionine synthesis, reducing systemic toxicity while treating refractory malignancies.

A secreted splicing variant of the mammal Klotho protein enhances cognitive performance and memory capabilities.

Substituted pyrido[3,2-d]pyrimidine compounds bind the colchicine site on microtubules to disrupt tubulin assembly and inhibit cancer cell proliferation.

Identified CYP88E3 gene encoding triterpene oxidase resolves unknown biosynthetic pathway bottlenecks to stabilize glycyrrhizin yields.

A humanized monoclonal antibody binds the HERV-W envelope protein to neutralize viral particles.

Formula I compounds act as TGFβ receptor antagonists to modulate signaling pathways in proliferative disorders.

Modified nucleobase nanocapsule shells self-assemble into hydrogels via hydrogen bonding, eliminating polymeric excipients that cause systemic toxicity.

Liver-specific enzyme activation of a phenanthroline phosphonic acid prodrug targets fibrosis while sparing other organs.

Single matrix layer formulation using alpha-hydroxy acid enables seven-day buprenorphine flux, bypassing gastrointestinal irritation from frequent oral dosing.